Biodesix (BDSX)

• Market cap: $228M
• 1 day: 15.44%
• 5 days: 18.05%
• 1 month: 31.93%
• 3 months: -12.78%
• 6 months: -2.48%
• Year to date: -11.80%
• 1 year: -4.85%
• 5 years: -87.74%
• 10 years: -87.74%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Employees: 217

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

36% more capital invested

Capital invested by funds: $81.8M [Q2] → $111M (+$29.1M) [Q3]

13% more funds holding

Funds holding: 46 [Q2] → 52 (+6) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

3.74% less ownership

Funds ownership: 46.6% [Q2] → 42.86% (-3.74%) [Q3]

67% less call options, than puts

Call options by funds: $6K | Put options by funds: $18K